PEPG INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that PepGen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

1. A class action lawsuit has been filed against PepGen Inc. 2. Allegations include misleading statements regarding the drug PGN-EDO51. 3. The lawsuit targets securities purchased between March 7, 2024, and March 3, 2025. 4. The CONNECT2 study's safety and effectiveness were called into question. 5. Investors are encouraged to join the case for potential recovery.

Legal

85

5m saved

Insight

Article

FAQ

Why Very Bearish?

Class action lawsuits typically lead to a decrease in stock price as investor confidence erodes. Historically, companies facing such lawsuits often see significant sell-offs due to perceived risks associated with litigation outcomes.

How important is it?

The lawsuit's nature indicates potential financial repercussions for the company, directly affecting investor sentiment and stock behavior. Legal issues in biotech often unfavorably influence valuations, hence the high importance score.

Why Long Term?

The impact of litigation can persist over time, especially if the case delays project timelines or affects regulatory approvals. The credibility of the company could be diminished in the long run, affecting future stock performance akin to past instances like Theranos.

Related Companies

VRTX AMGN

NEW YORK, June 13, 2025 /PRNewswire/ -- Attorney Advertising

Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against PepGen Inc. ("PepGen" or "the Company") (NASDAQ: PEPG) and certain of its officers.

Class Definition

This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired PepGen securities between March 7, 2024 and March 3, 2025, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: bgandg.com/PEPG.

Case Details

The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) PGN-EDO51 was less effective and safe than Defendants had led investors to believe; (ii) the CONNECT2 study was dangerous or otherwise deficient for purposes of U.S. Food and Drug Administration ("FDA") approval; (iii) as a result of all the foregoing, PepGen was likely to halt the CONNECT2 study, and PGN-EDO51's clinical, regulatory, and commercial prospects were overstated; and (iv) as a result, Defendants' public statements were materially false and misleading at all relevant times.

What's Next?

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm's site: bgandg.com/PEPG, or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660. If you suffered a loss in PepGen you have until August 8, 2025, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.

There is No Cost to You

We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

Follow us for updates on LinkedIn, X, Facebook, or Instagram.

Attorney advertising. Prior results do not guarantee similar outcomes.

Contact

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | [email protected]

SOURCE Bronstein, Gewirtz & Grossman, LLC